Equillium

EQPhase 2

Equillium is pioneering immunobiology-based treatments for severe autoimmune and inflammatory conditions through two distinct technology platforms. Its lead asset, itolizumab (EQ001), is in multiple Phase 1b trials for acute GVHD, systemic lupus erythematosus, and lupus nephritis, while its novel AhR modulator, EQ504, represents a non-immunosuppressive approach to tissue repair and inflammation. The company's strategy centers on modulating key immune pathways to address diseases with significant unmet need, positioning itself as a leader in next-generation immunomodulation.

Market Cap

$137.6M

Focus

AntibodiesBiologics

EQ · Stock Price

USD 2.2611.74 (-83.86%)

Historical price data

AI Company Overview

Technology Platform

Equillium utilizes two core platforms: 1) A Multi-Cytokine Inhibitor Platform producing structured-domain peptides that selectively inhibit multiple disease-driving cytokines, and 2) An AhR Modulation Platform targeting the aryl hydrocarbon receptor for non-immunosuppressive regulation of barrier function, tissue repair, and anti-inflammatory responses.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
BNZ-1 + Normal saline	Alopecia Areata	Phase 2
EQ101	Alopecia Areata	Phase 2

Funding History

Total raised: $175M

IPO$75MUndisclosedOct 11, 2018

Series B$60MRedmile GroupJun 15, 2018

Series A$40MLilly VenturesOct 15, 2017

Opportunities

Equillium has significant growth opportunities in large autoimmune and inflammatory disease markets with high unmet needs, particularly in acute GVHD and lupus nephritis where current treatments are inadequate.

The company's novel mechanisms (CD6 modulation via itolizumab and AhR modulation via EQ504) could capture market share by offering improved safety profiles compared to broad immunosuppressants.

Strategic partnerships with larger pharmaceutical companies could accelerate development and provide non-dilutive funding.

Risk Factors

Key risks include clinical trial failures, regulatory hurdles, intense competition from well-funded biopharma companies, financial dependency on capital markets, and the unproven nature of Equillium's novel therapeutic mechanisms.

The company's pre-revenue status and need for additional funding create significant financial risk, particularly in volatile biotech markets.

Competitive Landscape

Equillium faces competition from established players like Incyte (ruxolitinib in GVHD), GlaxoSmithKline (belimumab in lupus), and various asthma biologic manufacturers. Differentiation lies in itolizumab's unique CD6-targeting mechanism that modulates T cell activity and trafficking without broad immunosuppression, and EQ504's novel AhR modulation approach distinct from current cytokine-targeting strategies.